WO2015077789A2 - Récepteurs d'antigènes chimériques pour lutter contre une infection par le vih - Google Patents

Récepteurs d'antigènes chimériques pour lutter contre une infection par le vih Download PDF

Info

Publication number
WO2015077789A2
WO2015077789A2 PCT/US2014/067459 US2014067459W WO2015077789A2 WO 2015077789 A2 WO2015077789 A2 WO 2015077789A2 US 2014067459 W US2014067459 W US 2014067459W WO 2015077789 A2 WO2015077789 A2 WO 2015077789A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
hiv
car
domain
cells
Prior art date
Application number
PCT/US2014/067459
Other languages
English (en)
Other versions
WO2015077789A3 (fr
Inventor
Edward A. Berger
Li Liu
Bhavik Patel
Steven A. Rosenberg
Richard A. Morgan
Mustafa H. GHANEM
Barna Dey
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority to US15/039,384 priority Critical patent/US10246505B2/en
Priority to AU2014352638A priority patent/AU2014352638B2/en
Priority to CA2930587A priority patent/CA2930587A1/fr
Priority to EP14812376.3A priority patent/EP3074419B1/fr
Publication of WO2015077789A2 publication Critical patent/WO2015077789A2/fr
Publication of WO2015077789A3 publication Critical patent/WO2015077789A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette divulgation concerne de nouvelles protéines de type récepteurs d'antigènes chimériques multispécifiques (CAR) et des séquences d'ADN codant pour ces protéines. Les CAR comprennent au moins deux domaines extracellulaires fusionnés, par l'intermédiaire d'un domaine transmembranaire à un domaine de signalisation cytoplasmique comprenant deux domaines de signalisation. Cette divulgation concerne en outre des acides nucléiques codant pour lesdits nouveaux CAR, des cellules hôtes les exprimant, des méthodes d'utilisation desdits CAR pour co-stimuler des fonctions effectrices dans les cellules et des méthodes d'utilisation des cellules exprimant lesdits récepteurs pour traiter des maladies et des infections virales. Des méthodes destinées à générer une cellule T recombinée ayant une sensibilité réduite à une infection par le VIH sont en outre décrites.
PCT/US2014/067459 2013-11-25 2014-11-25 Récepteurs d'antigènes chimériques pour lutter contre une infection par le vih WO2015077789A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US15/039,384 US10246505B2 (en) 2013-11-25 2014-11-25 Chimeric antigen receptors to control HIV infection
AU2014352638A AU2014352638B2 (en) 2013-11-25 2014-11-25 Chimeric antigen receptors to control HIV infection
CA2930587A CA2930587A1 (fr) 2013-11-25 2014-11-25 Recepteurs d'antigenes chimeriques pour lutter contre une infection par le vih
EP14812376.3A EP3074419B1 (fr) 2013-11-25 2014-11-25 Récepteurs d'antigènes chimériques pour lutter contre une infection par le vih

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361908691P 2013-11-25 2013-11-25
US61/908,691 2013-11-25
US201462040398P 2014-08-21 2014-08-21
US62/040,398 2014-08-21

Publications (2)

Publication Number Publication Date
WO2015077789A2 true WO2015077789A2 (fr) 2015-05-28
WO2015077789A3 WO2015077789A3 (fr) 2015-08-13

Family

ID=52101618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/067459 WO2015077789A2 (fr) 2013-11-25 2014-11-25 Récepteurs d'antigènes chimériques pour lutter contre une infection par le vih

Country Status (5)

Country Link
US (1) US10246505B2 (fr)
EP (1) EP3074419B1 (fr)
AU (1) AU2014352638B2 (fr)
CA (1) CA2930587A1 (fr)
WO (1) WO2015077789A2 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017053556A1 (fr) * 2015-09-22 2017-03-30 The Trustees Of The University Of Pennsylvania Méthode de réacheminement de lymphocytes t pour le traitement d'une infection par le vih
WO2017123556A1 (fr) * 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Protéines chimériques et procédés d'immunothérapie
WO2017173256A1 (fr) * 2016-04-01 2017-10-05 Kite Pharma, Inc. Récepteurs antigéniques chimériques et récepteurs de lymphocytes t et leurs procédés d'utilisation
US9856497B2 (en) 2016-01-11 2018-01-02 The Board Of Trustee Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
WO2018027197A1 (fr) * 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cibles d'antigène du cancer et leurs utilisations
CN107987173A (zh) * 2017-11-30 2018-05-04 山东兴瑞生物科技有限公司 双靶点嵌合抗原受体、其编码基因、具有该基因质粒、免疫t效应细胞及hiv-1应用
WO2019060425A1 (fr) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions pour la thérapie par lymphocytes t à récepteur antigénique chimérique et leurs utilisations
WO2019126464A2 (fr) 2017-12-20 2019-06-27 Lentigen Technology, Inc. Compositions et méthodes pour le traitement du vih/sida par immunothérapie
WO2019161281A1 (fr) 2018-02-17 2019-08-22 Flagship Pioneering Innovations V, Inc. Compositions et procédés d'administration de protéines membranaires
EP3511347A4 (fr) * 2017-06-28 2019-10-16 Wuhan Bio-Raid Biotechnology Co., Ltd Construction d'un gène recombiné de récepteur d'antigène chimérique pour le traitement d'une infection par le vih, et application associée
WO2020038490A1 (fr) * 2018-08-24 2020-02-27 杭州优善生物科技有限公司 Agent thérapeutique comprenant un acide nucléique et des cellules immunitaires modifiées pour exprimer un car, et application de celui-ci
US10597456B2 (en) 2016-04-01 2020-03-24 Amgen Inc. Chimeric receptors and methods of use thereof
WO2020123444A1 (fr) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Procédés d'utilisation d'anticorps cd27 en tant que traitement de conditionnement pour une thérapie cellulaire adoptive
US10689450B2 (en) 2016-04-01 2020-06-23 Kite Pharma, Inc BCMA binding molecules and methods of use thereof
WO2020191305A2 (fr) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Utilisations d'amphiphiles en thérapie cellulaire immunitaire et compositions associées
US11142565B2 (en) 2015-09-24 2021-10-12 Abvitro Llc Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
EP3737688A4 (fr) * 2018-01-10 2021-11-03 The General Hospital Corporation Cellules immunitaires exprimant un récepteur antigénique chimérique
WO2021221782A1 (fr) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Ligands chimériques ciblant des récepteurs antigéniques et leurs utilisations
WO2021221783A1 (fr) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Procédés d'identification de ligands de ciblage de récepteur antigénique chimérique et leurs utilisations
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2540694A (en) * 2014-04-29 2017-01-25 Seattle Children's Hospital (Dba Seattle Children's Res Institute) CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
EP3407919A4 (fr) * 2016-01-28 2019-09-04 The Regents of the University of California Méthodes de multiplication et d'enrichissement sélectifs de cellules transduites avec des récepteurs d'antigènes chimériques et de traitement d'une infection par le vih
US20200270573A1 (en) * 2017-11-07 2020-08-27 Temple University-Of The Commonwealth System Of Higher Education Compositions and methods for improved t cells
AU2019284649A1 (en) * 2018-06-12 2021-01-14 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptor tumor infiltrating lymphocytes
US11760786B2 (en) * 2019-02-06 2023-09-19 The Regents Of The University Of Michigan Chimeric antigen receptors targeting abnormal glycobiology
CN114805611A (zh) * 2022-06-28 2022-07-29 上海荧辉医疗器械有限公司 靶向末端甘露糖的嵌合抗原受体及其应用

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
US5587455A (en) 1988-07-23 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Cytotoxic agent against specific virus infection
US5589466A (en) 1989-03-21 1996-12-31 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
US5696237A (en) 1986-09-24 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant antibody-toxin fusion protein
US5695927A (en) 1988-03-31 1997-12-09 The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology Monoclonal antibodies specific for HIV and the hybridomas for production thereof
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5767260A (en) 1994-10-13 1998-06-16 Enzon Inc. Antigen-binding fusion proteins
WO1998036087A1 (fr) 1997-02-13 1998-08-20 American National Red Cross Tolerance immunologique aux epitopes du hiv
US5843454A (en) 1993-05-07 1998-12-01 Akzo Nobel N.V. HIV immunogenic complexes
US5856456A (en) 1992-11-20 1999-01-05 Enzon, Inc. Linker for linked fusion polypeptides
US6027890A (en) 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US6117655A (en) 1987-10-02 2000-09-12 Genentech, Inc. Nucleic acid encoding adhesion variants
US6329202B1 (en) 1992-12-31 2001-12-11 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding associated epitopes
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
WO2012079000A1 (fr) 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Utilisation de lymphocytes t modifiés par un récepteur chimérique d'antigènes chimérique pour traiter le cancer
US20120213783A1 (en) 2009-10-01 2012-08-23 Rosenberg Steven A Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2013059593A1 (fr) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs d'antigènes chimériques anti-cd22
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5696237A (en) 1986-09-24 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant antibody-toxin fusion protein
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US6117655A (en) 1987-10-02 2000-09-12 Genentech, Inc. Nucleic acid encoding adhesion variants
US5695927A (en) 1988-03-31 1997-12-09 The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology Monoclonal antibodies specific for HIV and the hybridomas for production thereof
US5587455A (en) 1988-07-23 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Cytotoxic agent against specific virus infection
US5589466A (en) 1989-03-21 1996-12-31 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
US5856456A (en) 1992-11-20 1999-01-05 Enzon, Inc. Linker for linked fusion polypeptides
US6329202B1 (en) 1992-12-31 2001-12-11 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding associated epitopes
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5843454A (en) 1993-05-07 1998-12-01 Akzo Nobel N.V. HIV immunogenic complexes
US5767260A (en) 1994-10-13 1998-06-16 Enzon Inc. Antigen-binding fusion proteins
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US6027890A (en) 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
WO1998036087A1 (fr) 1997-02-13 1998-08-20 American National Red Cross Tolerance immunologique aux epitopes du hiv
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
US8420099B2 (en) 1999-03-16 2013-04-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
US20120213783A1 (en) 2009-10-01 2012-08-23 Rosenberg Steven A Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2012079000A1 (fr) 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Utilisation de lymphocytes t modifiés par un récepteur chimérique d'antigènes chimérique pour traiter le cancer
WO2013059593A1 (fr) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs d'antigènes chimériques anti-cd22
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation

Non-Patent Citations (102)

* Cited by examiner, † Cited by third party
Title
"Antibody Engineering", vol. 1-2, 2010, SPRINGER PRESS
"Molecular Biology and Biotechnology: a Comprehensive Desk Reference", 1995, VCH PUBLISHERS, INC.
"Pierce Catalog and Handbook", 1994, PIERCE CHEMICAL CO.
"Principles of Pharmacology", 1995
"Remington's Pharmaceutical Science", 1995, MACK PUBLISHING COMPANY
"The Encyclopedia of Molecular Biology", 1994, BLACKWELL SCIENCE LTD.
AHMAD ET AL., CLIN. DEV. IMMUNOL., 2012
AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948
ALMEIDA ET AL., BLOOD, vol. 113, no. 25, 2009, pages 6351 - 6360
ALTSCHUL, NATURE GENET., vol. 6, 1994, pages 119 - 129
ALTSCHUL, T MOD BIOD, vol. 215, 1990, pages 403 - 410
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 2013, JOHN WILEY & SONS
BENJAMIN LEWIN: "Genes V", 1994, OXFORD UNIVERSITY PRESS
BIRD, SCIENCE, vol. 242, 1988, pages 423 - 426
BRENTJENS ET AL., MOLECULAR THERAPY, vol. 18, no. 4, 2010, pages 666 - 668
CARTER ET AL., PROC. NATL. ACAD. SCI., vol. 89, 1992, pages 4285 - 4289
CONNOR ET AL., PEDIATR INFECT DIS J, vol. 14, 1994, pages 536 - 541
CORPET, NUC. ACIDS RES., vol. 16, 1988, pages 10881 - 10890
DEAN, CELL TISSUE KINET, vol. 13, 1980, pages 299 - 308
DEAN, CELL TISSUE KINET., vol. 13, 1980, pages 672 - 681
DEEKS ET AL., MOLECULAR THERAPY, vol. 5, no. 6, 2002, pages 788 - 797
DOYLE ET AL.: "Cell and Tissue Culture: Laboratory Procedures", 1994, WILEY
DRICKAMER ET AL., J. BIOL. CHEM, vol. 23, 1988, pages 9557 - 9560
E. W. MARTIN: "Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING CO.
FAHA ET AL., J. VIROL., vol. 67, 1993, pages 2456 - 2465
FARZAN ET AL., J. VIROL., vol. 79, 2005, pages 6068 - 77
FARZAN, J. VIROL., vol. 79, 2005, pages 6068 - 77
FEINBERG ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 4202 - 4209
FEINBERG ET AL., SCIENCE, vol. 294, 2001, pages 2163 - 2166
GERSHONI, FASEB .I, vol. 7, 1993, pages 1185 - 1187
GRUPP ET AL., N ENGL J MED., vol. 368, 2013, pages 1509 - 1518
HAMERS-CASTERMAN, NATURE, vol. 363, 1993, pages 446 - 448
HAN ET AL., J. HEMATOL ONCOL., vol. 6, 2013, pages 47
HARLOW; LANE: "Antibodies, A Laboratory Manual", 2013, COLD SPRING HARBOR PUBLICATIONS
HASO ET AL., BLOOD, vol. 121, 2013, pages 1165 - 1174
HENNECKE, PROTEIN ENG., vol. 11, 1998, pages 405 - 410
HERSCHHORN ET AL., PLOS ONE, vol. 6, no. 11, 2011, pages E26731
HIGGINS; SHARP, CABIOS, vol. 5, 1989, pages 151 - 153
HIGGINS; SHARP, GENE, vol. 73, 1988, pages 237 - 244
HOLLIGER, PROC. NATL. ACAD. SCI., vol. 90, 1993, pages 6444 - 6448
HUANG, COMP. APPLS. BIOSCI., vol. 8, 1992, pages 155 - 165
HUSTON ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 5879 - 5883
JAMESON ET AL., J VIROL, vol. 76, 2002, pages 1866 - 1875
JONES ET AL., HUMAN GENE THERAPY, vol. 20, 2009, pages 630 - 640
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH
KABAT: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
KARN: "HIV: a practical approach", 1995, OXFORD UNIV. PRESS
KINDT ET AL.: "Kuby Immunology", 2007, W.H. FREEMAN AND CO., pages: 91
KUBY: "Immunology", 1997, W.H. FREEMAN & CO.
KWONG ET AL., J. BIOD. CHEM., vol. 274, 1999, pages 4115 - 4123
KWONG ET AL., NATURE, vol. 393, 1998, pages 648 - 659
KWONG, NATURE, vol. 393, 1998, pages 648 - 659
LAGENAUR ET AL., RETROVIROLO GY, vol. 7, 2010, pages 11
LAGENAUR ET AL., RETROVIROLOGY, vol. 7, 2010, pages 11
LEFRANC ET AL.: "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains", DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77, XP055144492, DOI: doi:10.1016/S0145-305X(02)00039-3
MADDON, CELL, vol. 42, 1985, pages 93
MARBRY, IDRUGS, vol. 13, 2010, pages 543 - 549
MARTIN ET AL., NATURE BIOTECH, vol. 21, 2003, pages 71 - 76
MITSUYASU ET AL., BLOOD, vol. 96, no. 3, 2000, pages 785 - 793
MONDOR ET AL., J. VIROL., vol. 72, 1998, pages 3623 - 3634
MORGAN ET AL., MOLECULAR THERAPY, 23 February 2010 (2010-02-23), pages 1 - 9
MOULARD, PNAS, vol. 99, 2002, pages 6913 - 6918
MYERS; MILLER, CABIOS, vol. 4, 1989, pages 11 - 17
NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453
NORA ET AL., RETROVIROL., vol. 5, 2008, pages 1 - 16
NUSSBAUM ET AL., J. VIROL., vol. 68, 1994, pages 5411 - 5422
PARK ET AL., TRENDS BIOTECHNOL., vol. 29, 2011, pages 550 - 557
PEARSON ET AL., METHODS IN MOLECULAR BIOLOGY, vol. 24, 1994, pages 307 - 331
PEARSON; LIPMAN, PROC. NATL. ACAD. SCI., USA, vol. 85, 1988, pages 2444 - 2448
PLOS ONE, vol. 7, no. 1, 2012
POLJAK ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123
REEVES ET AL., J. VIROL., vol. 79, 2005, pages 4991 - 4999
REITER ET AL., PROTEIN ENGINEERING, vol. 7, 1994, pages 697 - 704
SAKIHAMA, PROC. NATL. ACAD. SCI., vol. 92, 1995, pages 6444
SALZWEDEL ET AL., J. VIROL., vol. 74, 2000, pages 326 - 333
SALZWEDEL, J. VIROL., vol. 74, 2000, pages 326 - 333
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2000, COLD SPRING HARBOR LABORATORY PRESS
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR
SAMBROOK: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR
SATTENTAU, CURRENT OPINION IN VIROLOGY, vol. 1, no. 5, 2011, pages 396 - 402
SCHOLLER ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 4, no. 132, 2012
SHERIFF ET AL., NAT. STRUCT. BIOL., vol. 1, 1994, pages 789 - 794
SHERIFF, NAT. STRUCT. BIOL., vol. 3, 1996, pages 733 - 736
SMITH; WATERMAN, ADV. A PL MATH., vol. 2, 1981, pages 482
SNYDER ET AL., CURR. HIV RES., vol. 1, no. 3, 2003, pages 287 - 294
STOVER, NATURE, vol. 351, 1991, pages 456 - 460
THALI ET AL., J. VIROL, vol. 67, 1993, pages 3978 - 3988
TIJSSEN: "Laboratory Techniques in Biochemistry and Molecular Biology", 1993, ELSEVIER
TILL ET AL., BLOOD, vol. 1, no. 12, 2008, pages 2261 - 2271
TIMOTHY SPRINGER, DE ET AL., J EXP MED., vol. 175, no. 1, 1992, pages 185 - 90
TRKOLA ET AL., J VIRO|, vol. 69, 1995, pages 6609 - 6617
TRKOLA, JOURNAL OF VIROLOGY, vol. 69, 1995, pages 6609 - 6617
TUMAINI ET AL., CYTOTHERAPY, vol. 15, 2013, pages 1406 - 1417
WALKER ET AL., BLOOD, vol. 96, no. 2, 2000, pages 467 - 474
WALKER ET AL., SCIENCE, vol. 326, 2009, pages 285 - 289
WALKER, NATURE, vol. 477, 2011, pages 466 - 470
WALKER, SCIENCE, vol. 326, 2009, pages 285 - 289
WALTERS: "Pharmaceutical Biotechnology", 1993, INTERPHARM PRESS, article "Computer-Assisted Modeling of Drugs", pages: 165 - 174
WATKINS ET AL., PLOS ONE, vol. 6, 2011, pages E18207
WATKINS, PL S ONE, vol. 6, 2011, pages E18207
ZHAO ET AL., J. IMMUNOL., vol. 183, 2009, pages 5563 - 5574

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108779161A (zh) * 2015-09-22 2018-11-09 宾夕法尼亚大学董事会 重定向t细胞以治疗hiv感染的方法
US10738099B2 (en) 2015-09-22 2020-08-11 The Trustees Of The University Of Pennsylvania Method of redirecting T cells to treat HIV infection
JP6991131B2 (ja) 2015-09-22 2022-02-03 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｉｖ感染症を処置するためにｔ細胞を再度方向付ける方法
WO2017053556A1 (fr) * 2015-09-22 2017-03-30 The Trustees Of The University Of Pennsylvania Méthode de réacheminement de lymphocytes t pour le traitement d'une infection par le vih
JP2018527014A (ja) * 2015-09-22 2018-09-20 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｉｖ感染症を処置するためにｔ細胞を再度方向付ける方法
US11142565B2 (en) 2015-09-24 2021-10-12 Abvitro Llc Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
US11572403B2 (en) 2015-09-24 2023-02-07 Abvitro Llc Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
US9856497B2 (en) 2016-01-11 2018-01-02 The Board Of Trustee Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
US10457961B2 (en) 2016-01-11 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
US11111287B2 (en) 2016-01-11 2021-09-07 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of immunotherapy
US11773411B2 (en) 2016-01-11 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
US10336807B2 (en) 2016-01-11 2019-07-02 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of immunotherapy
WO2017123556A1 (fr) * 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Protéines chimériques et procédés d'immunothérapie
IL261941B1 (en) * 2016-04-01 2023-07-01 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
US10689450B2 (en) 2016-04-01 2020-06-23 Kite Pharma, Inc BCMA binding molecules and methods of use thereof
JP7379561B2 (ja) 2016-04-01 2023-11-14 カイト ファーマ インコーポレイテッド キメラ抗原及びｔ細胞受容体、並びに使用方法
US10597456B2 (en) 2016-04-01 2020-03-24 Amgen Inc. Chimeric receptors and methods of use thereof
US10603380B2 (en) 2016-04-01 2020-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
TWI691596B (zh) * 2016-04-01 2020-04-21 美商凱特製藥公司 嵌合抗原和ｔ細胞受體及使用方法
AU2017240667C1 (en) * 2016-04-01 2022-11-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
JP2019516350A (ja) * 2016-04-01 2019-06-20 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａ キメラ抗原及びｔ細胞受容体、並びに使用方法
US11505613B2 (en) 2016-04-01 2022-11-22 Kite Pharma, Inc. BCMA binding molecules and methods of use thereof
JP2022078179A (ja) * 2016-04-01 2022-05-24 カイト ファーマ インコーポレイテッド キメラ抗原及びｔ細胞受容体、並びに使用方法
AU2017240667B2 (en) * 2016-04-01 2022-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
JP7034934B2 (ja) 2016-04-01 2022-03-14 カイト ファーマ インコーポレイテッド キメラ抗原及びｔ細胞受容体、並びに使用方法
WO2017173256A1 (fr) * 2016-04-01 2017-10-05 Kite Pharma, Inc. Récepteurs antigéniques chimériques et récepteurs de lymphocytes t et leurs procédés d'utilisation
TWI787599B (zh) * 2016-04-01 2022-12-21 美商凱特製藥公司 嵌合抗原和ｔ細胞受體及使用方法
US11193938B2 (en) 2016-08-04 2021-12-07 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
WO2018027197A1 (fr) * 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cibles d'antigène du cancer et leurs utilisations
EP3511347A4 (fr) * 2017-06-28 2019-10-16 Wuhan Bio-Raid Biotechnology Co., Ltd Construction d'un gène recombiné de récepteur d'antigène chimérique pour le traitement d'une infection par le vih, et application associée
WO2019060425A1 (fr) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions pour la thérapie par lymphocytes t à récepteur antigénique chimérique et leurs utilisations
CN107987173A (zh) * 2017-11-30 2018-05-04 山东兴瑞生物科技有限公司 双靶点嵌合抗原受体、其编码基因、具有该基因质粒、免疫t效应细胞及hiv-1应用
EP3728307A4 (fr) * 2017-12-20 2021-05-19 Lentigen Technology, Inc. Compositions et méthodes pour le traitement du vih/sida par immunothérapie
JP2021506306A (ja) * 2017-12-20 2021-02-22 レンティジェン・テクノロジー・インコーポレイテッドＬｅｎｔｉｇｅｎ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 免疫療法を用いてｈｉｖ／ａｉｄｓを処置するための組成物および方法
US10894819B2 (en) 2017-12-20 2021-01-19 Lentigen Technology, Inc. Compositions and methods for treating HIV/AIDS with immunotherapy
CN111954677A (zh) * 2017-12-20 2020-11-17 莱蒂恩技术公司 用于用免疫治疗来治疗hiv/aids的组合物和方法
WO2019126464A2 (fr) 2017-12-20 2019-06-27 Lentigen Technology, Inc. Compositions et méthodes pour le traitement du vih/sida par immunothérapie
JP7377802B2 (ja) 2017-12-20 2023-11-10 レンティジェン・テクノロジー・インコーポレイテッド 免疫療法を用いてｈｉｖ／ａｉｄｓを処置するための組成物および方法
EP3737688A4 (fr) * 2018-01-10 2021-11-03 The General Hospital Corporation Cellules immunitaires exprimant un récepteur antigénique chimérique
WO2019161281A1 (fr) 2018-02-17 2019-08-22 Flagship Pioneering Innovations V, Inc. Compositions et procédés d'administration de protéines membranaires
JP2021536435A (ja) * 2018-08-24 2021-12-27 杭州康万達医薬科技有限公司Hangzhou Converd Co., Ltd. 核酸とｃａｒ修飾免疫細胞とを含む治療薬およびその使用
WO2020038490A1 (fr) * 2018-08-24 2020-02-27 杭州优善生物科技有限公司 Agent thérapeutique comprenant un acide nucléique et des cellules immunitaires modifiées pour exprimer un car, et application de celui-ci
WO2020123444A1 (fr) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Procédés d'utilisation d'anticorps cd27 en tant que traitement de conditionnement pour une thérapie cellulaire adoptive
WO2020191305A2 (fr) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Utilisations d'amphiphiles en thérapie cellulaire immunitaire et compositions associées
WO2021221783A1 (fr) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Procédés d'identification de ligands de ciblage de récepteur antigénique chimérique et leurs utilisations
WO2021221782A1 (fr) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Ligands chimériques ciblant des récepteurs antigéniques et leurs utilisations
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity

Also Published As

Publication number Publication date
EP3074419B1 (fr) 2018-08-29
CA2930587A1 (fr) 2015-05-28
US20170267739A1 (en) 2017-09-21
WO2015077789A3 (fr) 2015-08-13
AU2014352638B2 (en) 2018-08-02
US10246505B2 (en) 2019-04-02
AU2014352638A1 (en) 2016-06-09
EP3074419A2 (fr) 2016-10-05

Similar Documents

Publication Publication Date Title
US10246505B2 (en) Chimeric antigen receptors to control HIV infection
AU2019203823B2 (en) CS1-specific chimeric antigen receptor engineered immune effector cells
US20230060304A1 (en) Neutralizing antibodies to gp120 and their use
CN114144430B (zh) Cd7-car-t细胞及其制备和应用
WO2013163427A1 (fr) Anticorps pour traiter les infections par le vih-1
TW202005980A (zh) 靶向hiv gp120之抗體及使用方法
WO2015103549A1 (fr) Anticorps neutralisants dirigés contre la env du vih-1 et leur utilisation
WO2016196975A1 (fr) Anticorps neutralisants dirigés contre la protéine d'enveloppe (env) du vih-1 et leur utilisation
Veillette et al. Role of HIV-1 envelope glycoproteins conformation and accessory proteins on ADCC responses
CN113874037A (zh) 鉴定对采用gp120 v3聚糖导向的抗体的疗法敏感的hiv患者的方法
US20230077100A1 (en) Anti-hpv t cell receptors and engineered cells
AU3889600A (en) A novel chimeric protein for prevention and treatment of hiv infection
TWI814130B (zh) 識別對具有ｇｐ１２０ＣＤ４結合部位導向抗體之療法敏感的ＨＩＶ患者之方法
WO2022159653A2 (fr) Récepteurs antigéniques chimériques bispécifiques se liant à cd19 et cd22
Alsahafi Protecting HIV-1-infected cells from ADCC: Role of Nef
Couto Synthetic antibodies targeting HIV-1 infectivity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14812376

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2930587

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014352638

Country of ref document: AU

Date of ref document: 20141125

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014812376

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014812376

Country of ref document: EP